Stay updated on Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial

Sign up to get notified when there's something new on the Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a multicenter, dose-escalating phase Ib clinical trial evaluating the safety and tolerability of GB226 in combination with fruquintinib for the treatment of metastatic colorectal cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:51.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria 6' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing a more detailed explanation of eligibility criteria and examples such as general health condition or prior treatments. This change likely pertains to medical and healthcare-related documentation, specifically in the context of clinical research studies.
    Difference
    57%
    Check dated 2024-05-22T21:13:03.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:39:50.000Z thumbnail image

Stay in the know with updates to Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page.